240 related articles for article (PubMed ID: 10666919)
1. [Clinical significance of allergen specific immunotherapy in adult house-dust-mite-sensitive bronchial asthma: impact on disease severity and medical cost].
Nagata M; Tabe K; Yamamoto H; Sakamoto Y; Matsuo H
Arerugi; 1999 Dec; 48(12):1316-21. PubMed ID: 10666919
[TBL] [Abstract][Full Text] [Related]
2. [An evaluation of the long-term effect of clustered immunotherapy in house-dust-mite-sensitive adult bronchial asthma].
Nagata M; Tanaka K
Arerugi; 2001 May; 50(5):435-9. PubMed ID: 11436329
[TBL] [Abstract][Full Text] [Related]
3. [A trial of new protocol of rush immunotherapy with standardized mite antigen].
Tabe K; Mizukoshi T; Nishi Y; Noguchi T; Shuh S; Kobayashi Y; Shibasaki M; Yamamoto H; Nagata M; Sakamoto Y; Matsuo H
Arerugi; 1999 May; 48(5):526-32. PubMed ID: 10390900
[TBL] [Abstract][Full Text] [Related]
4. [A clinical evaluation of clustered immunotherapy in house-dust-mite-sensitive adult bronchial asthma].
Nagata M
Arerugi; 1998 Apr; 47(4):426-33. PubMed ID: 9621470
[TBL] [Abstract][Full Text] [Related]
5. [Predicting the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics by multiple quantification analysis type II].
Soda R; Okada C; Takahashi K; Katagi S; Kanehiro A; Kimura G; Okamoto S; Tada S; Kimura I
Arerugi; 1993 Dec; 42(12):1771-5. PubMed ID: 8110037
[TBL] [Abstract][Full Text] [Related]
6. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study.
Bussmann C; Maintz L; Hart J; Allam JP; Vrtala S; Chen KW; Bieber T; Thomas WR; Valenta R; Zuberbier T; Sager A; Novak N
Clin Exp Allergy; 2007 Sep; 37(9):1277-85. PubMed ID: 17845407
[TBL] [Abstract][Full Text] [Related]
7. [The analysis of factors contributing to the safety and efficacy of rush immunotherapy in bronchial asthma].
Nagata M; Tabe K; Yamamoto H; Maruo H; Kiuch H; Sakamoto Y; Yamamoto K; Dohi Y
Arerugi; 1993 May; 42(5):628-34. PubMed ID: 8323461
[TBL] [Abstract][Full Text] [Related]
8. [A clinical evaluation of rush immunotherapy in adult patients with severe bronchial asthma].
Nagata M; Yamamoto H; Tabe K; Tanaka K; Kimura I; Sakamoto K; Sakamoto Y; Yamamoto K; Dohi Y
Arerugi; 1989 Dec; 38(12):1319-26. PubMed ID: 2634374
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of efficacy and safety of intrabronchial specific immunotherapy with allergy medication against allergies to house mites among patients with bronchial asthma].
Zietkowski Z
Pol Merkur Lekarski; 1999 May; 6(35):239-41. PubMed ID: 10437390
[TBL] [Abstract][Full Text] [Related]
10. [Allergen-specific immune therapy in the treatment of asthma].
Malling HJ
Ugeskr Laeger; 2000 Jan; 162(4):477-9. PubMed ID: 10697443
[TBL] [Abstract][Full Text] [Related]
11. [Preventive immunotherapy].
Boquete M; Carballada F; Expósito F; González A
Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
[TBL] [Abstract][Full Text] [Related]
12. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of mite asthma (author's transl)].
Kirsten D
Z Erkr Atmungsorgane; 1980; 155(1):120-4. PubMed ID: 7210736
[TBL] [Abstract][Full Text] [Related]
14. IgG, IgA, IgM and IgE serum levels in asthmatic patients sensitive to house dust and mite allergens after two-year specific immunotherapy.
Szymański W; Chyrek-Borowska S; Obrzut D
Arch Immunol Ther Exp (Warsz); 1984; 32(4):381-7. PubMed ID: 6534314
[TBL] [Abstract][Full Text] [Related]
15. [A study to predict the clinical efficacy of house dust mite immunotherapy in bronchial asthmatics].
Soda R; Takahashi K; Miyashita K; Katagi S; Yamagata K; Gotou M; Kimura G; Okamoto S; Okano T; Kawada N
Arerugi; 1993 Apr; 42(4):522-8. PubMed ID: 8323449
[TBL] [Abstract][Full Text] [Related]
16. Effect of immunotherapy in bronchial asthma: treatment with extracts of house dust and mite.
Choovoravech P
J Med Assoc Thai; 1974 Sep; 57(9):445-9. PubMed ID: 4418497
[No Abstract] [Full Text] [Related]
17. The immunological and clinical effects of immunotherapy in patients suffering from house dust allergy.
Chowdhury I; Chatterjee B
Ann Agric Environ Med; 1999; 6(2):91-7. PubMed ID: 10607989
[TBL] [Abstract][Full Text] [Related]
18. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite.
Maestrelli P; Zanolla L; Pozzan M; Fabbri LM;
J Allergy Clin Immunol; 2004 Apr; 113(4):643-9. PubMed ID: 15100667
[TBL] [Abstract][Full Text] [Related]
19. Rhinitis and asthma co-morbidity in respiratory allergy due to house dust mite: results of an observational open controlled parallel group study in real-life setting.
Marogna M; Spadolini I; Massolo A
Eur Ann Allergy Clin Immunol; 2005 Apr; 37(4):135-42. PubMed ID: 15916014
[TBL] [Abstract][Full Text] [Related]
20. The advances of hyposensibilisation therapy in bronchial asthma patients allergic to house dust antigen.
Romański B; Pawlik K; Wilawska-Kłubo T
Allerg Immunol (Leipz); 1977; 23(3):211-3. PubMed ID: 147019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
